Product Code: 978-1-68038-994-4
Computer-Aided Detection Market Summary
The global computer-aided detection market size was estimated at USD 936.6 million in 2024 projected to reach USD 1,497.1 million by 2033, growing at a CAGR of 5.19% from 2025 to 2033. Increasing cancer prevalence and raising awareness for regular health check-ups are the most significant drivers of the global computer-aided detection (CAD) industry.
The deaths due to cancer have led the governments to take various awareness initiatives, along with the key industry contributors, to come up with breakthrough imaging technologies. According to an article published by the American Cancer Society (ACS), 42,250 women deaths from breast cancer were estimated in 2024, with 310,720 new instances of invasive breast cancer. Women aged 70 and over accounted for more than 50% of all breast cancer-related deaths. The applications of CAD in cancer detection and treatment act as a driving force for the market's growth.
Over the last two decades, the diagnostic cancer imaging field has witnessed remarkable evolution and has affected cancer research and clinical management. Tobacco smoking is one of the most common causes of lung cancer and is a leading cause of death in the U.S. Moreover, the number of deaths in women from smoking is expected to increase rapidly over the forecast period. According to ACS, cancer accounted for 1 in 5 deaths in the U.S. Among these, smoking is responsible for 30% of all cancer fatalities and 20% of all cancer cases.
In addition, according to the World Health Organization (WHO) estimates, in 2022, cancer is the leading cause of death worldwide, resulting in approximately 10 million deaths in 2020, or nearly one in six deaths. The enhanced government initiatives to promote cancer awareness and treatment are anticipated to speed up the market's growth. For instance, the U.S. government relaunched the Cancer Moonshot in February 2022, aiming to cut the death rate from cancer by at least 50% over the following 25 years
Global Computer-Aided Detection Market Report Segmentation
This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global computer-aided detection market report based on application, indication, and region:
- Application Outlook (Revenue, USD Million, 2021 - 2033)
- Tuberculosis
- Breast cancer
- Lung cancer
- Colon cancer
- Prostate cancer
- Liver cancer
- Bone cancer
- Neurological/Musculoskeletal/Cardiovascular indications
- Indication Outlook (Revenue, USD Million, 2021 - 2033)
- X-Ray imaging
- Computed tomography
- Ultrasound imaging
- Magnetic resonance
- Nuclear medicine imaging
- Others
- Regional Outlook (Revenue, USD Million, 2021 - 2033)
- North America
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Thailand
- Latin America
- Middle East and Africa (MEA)
- South Africa
- Saudi Arabia
- UAE
- Kuwait
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.1.1. Application
- 1.1.2. Indication
- 1.1.3. Regional scope
- 1.1.4. Estimates and forecast timeline.
- 1.2. Research Methodology
- 1.3. Information Procurement
- 1.3.1. Purchased database.
- 1.3.2. GVR's internal database
- 1.3.3. Secondary sources
- 1.3.4. Primary research
- 1.3.5. Details of primary research
- 1.4. Information or Data Analysis
- 1.4.1. Data analysis models
- 1.5. Market Formulation & Validation
- 1.6. Model Details
- 1.6.1. Commodity flow analysis (Model 1)
- 1.6.2. Approach 1: Commodity flow approach
- 1.7. List of Secondary Sources
- 1.8. List of Primary Sources
- 1.9. Objectives
Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.2.1. Application outlook
- 2.2.2. Indication outlook
- 2.2.3. Regional outlook
- 2.3. Competitive Insights
Chapter 3. Computer-Aided Detection Market Variables, Trends & Scope
- 3.1. Market Dynamics
- 3.1.1. Market driver analysis
- 3.1.1.1. Rising cancer prevalence
- 3.1.1.2. Growing regulatory support
- 3.1.1.3. Technological advancement
- 3.1.2. Market restraint analysis
- 3.1.2.1. Limited awareness and training
- 3.1.2.2. High Implementation and Integration Costs
- 3.1.2.3. Data Privacy and Regulatory Challenges
- 3.1.3. Market opportunity analysis
- 3.1.4. Market challenge analysis
- 3.2. Computer-Aided Detection Market Analysis Tools
- 3.2.1. Industry Analysis - Porter's 5 Forces Model
- 3.2.1.1. Supplier power
- 3.2.1.2. Buyer power
- 3.2.1.3. Substitution threat
- 3.2.1.4. Threat of new entrant
- 3.2.1.5. Competitive rivalry
- 3.2.2. PESTEL Analysis
- 3.2.2.1. Political landscape
- 3.2.2.2. Economic landscape
- 3.2.2.3. Social landscape
- 3.2.2.4. Technological landscape
- 3.2.2.5. Environmental landscape
- 3.2.2.6. Legal landscape
- 3.2.3. Technological Overview
- 3.2.4. Case Study
Chapter 4. Computer-Aided Detection Market: Application Estimates & Trend Analysis
- 4.1. Application Market Share, 2024 & 2033
- 4.2. Segment Dashboard
- 4.3. Global Computer-Aided Detection Market by Application Outlook
- 4.4. Tuberculosis
- 4.4.1. Market estimates and forecast 2021 to 2033 (USD Million)
- 4.5. Breast Cancer
- 4.5.1. Market estimates and forecast 2021 to 2033 (USD Million)
- 4.6. Lung Cancer
- 4.6.1. Market estimates and forecast 2021 to 2033 (USD Million)
- 4.7. Colon/Rectal Cancer
- 4.7.1. Market estimates and forecast 2021 to 2033 (USD Million)
- 4.8. Prostate Cancer
- 4.8.1. Market estimates and forecast 2021 to 2033 (USD Million)
- 4.9. Liver Cancer
- 4.9.1. Market estimates and forecast 2021 to 2033 (USD Million)
- 4.10. Bone Cancer
- 4.10.1. Market estimates and forecast 2021 to 2033 (USD Million)
- 4.11. Neurological/Musculoskeletal/Cardiovascular Indications
- 4.11.1. Market estimates and forecast 2021 to 2033 (USD Million)
Chapter 5. Computer-Aided Detection Market: Indication Estimates & Trend Analysis
- 5.1. Indication Market Share, 2024 & 2033
- 5.2. Segment Dashboard
- 5.3. Global Computer-Aided Detection Market by Indication Outlook
- 5.4. X-Ray Imaging
- 5.4.1. Market estimates and forecast 2021 to 2033 (USD Million)
- 5.5. Computed Tomography
- 5.5.1. Market estimates and forecast 2021 to 2033 (USD Million)
- 5.6. Ultrasound Imaging
- 5.6.1. Market estimates and forecast 2021 to 2033 (USD Million)
- 5.7. Magnetic Resonance Imaging
- 5.7.1. Market estimates and forecast 2021 to 2033 (USD Million)
- 5.8. Nuclear Medicine Imaging
- 5.8.1. Market estimates and forecast 2021 to 2033 (USD Million)
- 5.9. Others
- 5.9.1. Market estimates and forecast 2021 to 2033 (USD Million)
Chapter 6. Computer-Aided Detection Market: Regional Estimates & Trend Analysis, By Application, By Indication
- 6.1. Regional Market Share Analysis, 2024 & 2033
- 6.2. Regional Market Dashboard
- 6.3. Global Regional Market Snapshot
- 6.4. Market Size & Forecasts Trend Analysis, 2021 to 2033:
- 6.5. North America
- 6.5.1. U.S.
- 6.5.1.1. Key country dynamics
- 6.5.1.2. Regulatory framework
- 6.5.1.3. Competitive scenario
- 6.5.1.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
- 6.5.2. Canada
- 6.5.2.1. Key country dynamics
- 6.5.2.2. Regulatory framework
- 6.5.2.3. Competitive scenario
- 6.5.2.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
- 6.5.3. Mexico
- 6.5.3.1. Key country dynamics
- 6.5.3.2. Regulatory framework
- 6.5.3.3. Competitive scenario
- 6.5.3.4. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
- 6.6. Europe
- 6.6.1. UK
- 6.6.1.1. Key country dynamics
- 6.6.1.2. Regulatory framework
- 6.6.1.3. Competitive scenario
- 6.6.1.4. UK market estimates and forecasts 2021 to 2033 (USD Million)
- 6.6.2. Germany
- 6.6.2.1. Key country dynamics
- 6.6.2.2. Regulatory framework
- 6.6.2.3. Competitive scenario
- 6.6.2.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
- 6.6.3. France
- 6.6.3.1. Key country dynamics
- 6.6.3.2. Regulatory framework
- 6.6.3.3. Competitive scenario
- 6.6.3.4. France market estimates and forecasts 2021 to 2033 (USD Million)
- 6.6.4. Italy
- 6.6.4.1. Key country dynamics
- 6.6.4.2. Regulatory framework
- 6.6.4.3. Competitive scenario
- 6.6.4.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
- 6.6.5. Spain
- 6.6.5.1. Key country dynamics
- 6.6.5.2. Regulatory framework
- 6.6.5.3. Competitive scenario
- 6.6.5.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
- 6.6.6. Norway
- 6.6.6.1. Key country dynamics
- 6.6.6.2. Regulatory framework
- 6.6.6.3. Competitive scenario
- 6.6.6.4. Norway market estimates and forecasts 2021 to 2033 (USD Million)
- 6.6.7. Sweden
- 6.6.7.1. Key country dynamics
- 6.6.7.2. Regulatory framework
- 6.6.7.3. Competitive scenario
- 6.6.7.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
- 6.6.8. Denmark
- 6.6.8.1. Key country dynamics
- 6.6.8.2. Regulatory framework
- 6.6.8.3. Competitive scenario
- 6.6.8.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
- 6.7. Asia Pacific
- 6.7.1. Japan
- 6.7.1.1. Key country dynamics
- 6.7.1.2. Regulatory framework
- 6.7.1.3. Competitive scenario
- 6.7.1.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
- 6.7.2. China
- 6.7.2.1. Key country dynamics
- 6.7.2.2. Regulatory framework
- 6.7.2.3. Competitive scenario
- 6.7.2.4. China market estimates and forecasts 2021 to 2033 (USD Million)
- 6.7.3. India
- 6.7.3.1. Key country dynamics
- 6.7.3.2. Regulatory framework
- 6.7.3.3. Competitive scenario
- 6.7.3.4. India market estimates and forecasts 2021 to 2033 (USD Million)
- 6.7.4. Australia
- 6.7.4.1. Key country dynamics
- 6.7.4.2. Regulatory framework
- 6.7.4.3. Competitive scenario
- 6.7.4.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
- 6.7.5. South Korea
- 6.7.5.1. Key country dynamics
- 6.7.5.2. Regulatory framework
- 6.7.5.3. Competitive scenario
- 6.7.5.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
- 6.7.6. Thailand
- 6.7.6.1. Key country dynamics
- 6.7.6.2. Regulatory framework
- 6.7.6.3. Competitive scenario
- 6.7.6.4. Singapore market estimates and forecasts 2021 to 2033 (USD Million)
- 6.8. Latin America
- 6.8.1. Brazil
- 6.8.1.1. Key country dynamics
- 6.8.1.2. Regulatory framework
- 6.8.1.3. Competitive scenario
- 6.8.1.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
- 6.8.2. Argentina
- 6.8.2.1. Key country dynamics
- 6.8.2.2. Regulatory framework
- 6.8.2.3. Competitive scenario
- 6.8.2.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
- 6.9. MEA
- 6.9.1. South Africa
- 6.9.1.1. Key country dynamics
- 6.9.1.2. Regulatory framework
- 6.9.1.3. Competitive scenario
- 6.9.1.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
- 6.9.2. Saudi Arabia
- 6.9.2.1. Key country dynamics
- 6.9.2.2. Regulatory framework
- 6.9.2.3. Competitive scenario
- 6.9.2.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
- 6.9.3. UAE
- 6.9.3.1. Key country dynamics
- 6.9.3.2. Regulatory framework
- 6.9.3.3. Competitive scenario
- 6.9.3.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
- 6.9.4. Kuwait
- 6.9.4.1. Key country dynamics
- 6.9.4.2. Regulatory framework
- 6.9.4.3. Competitive scenario
- 6.9.4.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 7. Competitive Landscape
- 7.1. Participant Overview
- 7.2. Company Market Position Analysis/ Share Analysis (2024)
- 7.3. Company Categorization
- 7.4. Strategy Mapping
- 7.5. Company Profiles/Listing
- 7.5.1. EDDA Technology, Inc.
- 7.5.1.1. Company overview
- 7.5.1.2. Financial performance
- 7.5.1.3. Product benchmarking
- 7.5.1.4. Strategic initiatives
- 7.5.2. FUJIFILM Holdings Corporation
- 7.5.2.1. Company overview
- 7.5.2.2. Financial performance
- 7.5.2.3. Product benchmarking
- 7.5.2.4. Strategic initiatives
- 7.5.3. Hologic, Inc.
- 7.5.3.1. Company overview
- 7.5.3.2. Financial performance
- 7.5.3.3. Product benchmarking
- 7.5.3.4. Strategic initiatives
- 7.5.4. Koninklijke Philips N.V
- 7.5.4.1. Company overview
- 7.5.4.2. Financial performance
- 7.5.4.3. Product benchmarking
- 7.5.4.4. Strategic initiatives
- 7.5.5. Siemens Healthineers AG
- 7.5.5.1. Company overview
- 7.5.5.2. Financial performance
- 7.5.5.3. Product benchmarking
- 7.5.5.4. Strategic initiatives
- 7.5.6. NANO-X IMAGING LTD.
- 7.5.6.1. Company overview
- 7.5.6.2. Financial performance
- 7.5.6.3. Product benchmarking
- 7.5.6.4. Strategic initiatives
- 7.5.7. CANON MEDICAL SYSTEMS CORPORATION
- 7.5.7.1. Company overview
- 7.5.7.2. Financial performance
- 7.5.7.3. Product benchmarking
- 7.5.7.4. Strategic initiatives
- 7.5.8. GE Healthcare
- 7.5.8.1. Company overview
- 7.5.8.2. Financial performance
- 7.5.8.3. Product benchmarking
- 7.5.8.4. Strategic initiatives
- 7.5.9. IBM
- 7.5.9.1. Company overview
- 7.5.9.2. Financial performance
- 7.5.9.3. Product benchmarking
- 7.5.9.4. Strategic initiatives
- 7.5.10. Riverain Technologies
- 7.5.10.1. Company overview
- 7.5.10.2. Financial performance
- 7.5.10.3. Product benchmarking
- 7.5.10.4. Strategic initiatives
- 7.5.11. iCAD, Inc.
- 7.5.11.1. Company overview
- 7.5.11.2. Financial performance
- 7.5.11.3. Product benchmarking
- 7.5.11.4. Strategic initiatives
- 7.5.12. Median Technologies
- 7.5.12.1. Company overview
- 7.5.12.2. Financial performance
- 7.5.12.3. Product benchmarking
- 7.5.12.4. Strategic initiatives
- 7.5.13. Hitachi, Ltd.
- 7.5.13.1. Company overview
- 7.5.13.2. Financial performance
- 7.5.13.3. Product benchmarking
- 7.5.13.4. Strategic initiatives
- 7.5.14. Shimadzu Analytical (India) Pvt. Ltd
- 7.5.14.1. Company overview
- 7.5.14.2. Financial performance
- 7.5.14.3. Product benchmarking
- 7.5.14.4. Strategic initiatives
- 7.5.15. Carestream Health
- 7.5.15.1. Company overview
- 7.5.15.2. Financial performance
- 7.5.15.3. Product benchmarking
- 7.5.15.4. Strategic initiatives
- 7.5.16. Esaote SPA
- 7.5.16.1. Company overview
- 7.5.16.2. Financial performance
- 7.5.16.3. Product benchmarking
- 7.5.16.4. Strategic initiatives
- 7.5.17. Quibim
- 7.5.17.1. Company overview
- 7.5.17.2. Financial performance
- 7.5.17.3. Product benchmarking
- 7.5.17.4. Strategic initiatives
- 7.5.18. Cleerly
- 7.5.18.1. Company overview
- 7.5.18.2. Financial performance
- 7.5.18.3. Product benchmarking
- 7.5.18.4. Strategic initiatives
- 7.5.19. Planmeca
- 7.5.19.1. Company overview
- 7.5.19.2. Financial performance
- 7.5.19.3. Product benchmarking
- 7.5.19.4. Strategic initiatives